Pioneering A. Catalyst Innovation Hub will embrace new technology including AI; Projects include key partnerships with Tricog Health in Kenya and Medsol AI in South Africa; New hub will focus on education, early diagnosis, technology, and data generation.
AstraZeneca, a leading global pharmaceutical company, launched the Africa Health Innovation Hub today. This ground-breaking initiative highlights the company’s commitment to healthcare equity and fostering partnerships with a range of stakeholders, including governments, healthcare societies, academia, healthcare providers and patient advocacy groups patient advocacy groups, to better improve patient outcomes. Building on AstraZeneca’s work in Africa, the hub aims to use the latest science and technology to improve access to healthcare for patients on the continent.
The Africa Health Innovation Hub is the latest in the global A. Catalyst Network (https://apo-opa.info/3zUAl3b), a connected array of over 20 hubs worldwide. This network seeks to tackle current healthcare challenges through collaborative innovation, promote affordable and equitable healthcare access, and amplify patient-centred innovation through strategic alliances within the healthcare ecosystem.
Last year, AstraZeneca has joined the WEF Edison Alliance, (https://apo-opa.info/3o4sPA1) a public-private partnership that aims to improve the lives of 1 billion people through digital inclusion by 2025. The partnership reinforces our commitment to harnessing digital innovation to drive inclusion and equity across the healthcare ecosystem, therefore, will also be a strong facilitator of the Africa Hub.
Gagan Singh, Country President, African Cluster, AstraZeneca, stated, “AstraZeneca aims to strengthen and future-proof health systems across the whole patient journey, ensuring everyone has equitable and affordable access to the life-changing healthcare solutions they need, regardless of where they live. The launch of the Africa Health Innovation Hub is a significant step in our goal to unlock digital transformation and innovation in health across the continent, paving the way for patient-centric digital health solutions that leave no one behind. By working with partners across the continent, we are nurturing local talent and making quality health care more accessible for all.”
Partnering to bring our purpose to life
In Africa, two major new partnerships will form the backbone of the Hub in its initial phases:
- In South Africa, AstraZeneca is partnering with MEDSOL AI SOLUTIONS (https://MEDSOL.AI) to help promote the use of AI in the detection of disease through a state-of-the-art Wi-Fi ultrasound probe that can detect breast cancer in seconds. The Melusi Breast AI rapid detection app will be rolled out in rural clinics to help in early detection of the disease, supported by a dedicated referral system so that women with positive detection of breast cancer can be offered a quicker turnaround time for therapeutic intervention.
Dr Kathryn Malherbe (PhD), CEO&Founder of MedSol AI Solutions said, “Medsol AI is excited to be leading one of the inaugural projects of the Africa Innovation Hub, with support from AstraZeneca. Breast cancer is a devastating disease, with many women in our communities only able to access late-stage diagnoses. The Melusi Breast AI project will enable us to leverage technology and innovation to improve early diagnostic detection rates and patient outcomes in local clinics, ultimately saving lives.”
- In Kenya, the company is expanding an already successful collaboration with Tricog (www.Tricog.com) Health Limited. After a few years of piloting an AI technology that connects ACS patients to health professionals and route them to the appropriate facilities, enabling early cardio-renal complications to be addressed in India, the African hub aims to enhance early diagnosis and treatment of Heart Failure using Tricog’s InstaECG AI tools for rapid diagnosis, reducing mortality rates and improving quality of life.
Dr. Charit Bhograj, CEO&Founder Tricog Health Limited added, “non-communicable diseases, including heart disease, are on the rise in Kenya and across Africa, and we know that the earlier these conditions are diagnosed, the better chance it is for patients to continue to live long healthy lives. By investing in digital health technology, the Africa Health Innovation Hub is enabling the use of advanced AI to screen and diagnose patients remotely, bringing high-quality health tools to people no matter where they live.”
Another partnership initiated last year and will officially form part of the Africa Health Innovation Hub is the Fuel Africa (https://apo-opa.info/3odJEsf) programme, launched by Futurize (www.Futurize.studio). This is the largest healthcare entrepreneurship programme on the continent, bringing together the brightest minds across universities in Sub-Saharan Africa to address some of Africa’s most pressing challenges in healthcare. For the second year in a row, AstraZeneca’s A. Catalyst Network partnered with Futurize to reinforce our strong commitment to fostering innovation in the continent by developing local talents.
Official kick off to AstraZeneca’s health innovation hub in Africa
The official launch event – which marked the launch of the hub and the kick off of the Medsol AI partnership – took place at the Daspoort Poli Clinic in Pretoria, South Africa, where healthcare practitioners were able to demonstrate the use of the Melusi Breast AI device in a community clinic setting, which is one of the first points of contact for clinical breast examinations and breast cancer screening for patients.
The Africa Health Innovation Hub will also invest in building local talent, promote policy change for cancer screening, close the gaps in healthcare access and improve the quality of life for patients in the African region, particularly in rural and underserved communities. These objectives are aligned with the four pillars of AstraZeneca’s A. Catalyst Network: Education and Awareness, Early Diagnosis and Referral, Connectivity and Technology, and Data Generation.
Distributed by APO Group on behalf of AstraZeneca.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal&Metabolism, and Respiratory&Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit AstraZeneca.com and follow the Company on Twitter @AstraZeneca.
About Tricog Health limited (www.Tricog.com):
Tricog Health Limited provides AI technology backed by human expertise to empower healthcare providers with remote cardiac diagnosis. It is a leader in the Medtech space in solving critical Cardiovascular conditions by identifying them in time and accurately.
About Medsol AI (https://MEDSOL.AI):
MedSol AI Solutions promotes early and accurate diagnosis of breast cancer leading to a significant reduction in mortality rates associated with breast cancer.